Market Overview

Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer

Why This Inovio Analyst Is Reducing Estimates For The Coronavirus Vaccine Developer

Inovio Pharmaceuticals Inc (NASDAQ: INO) failed to inspire confidence among investors despite revealing in its second-quarter earnings report that it is on track for a September start for a Phase 2/3 clinical study of its developmental DNA coronavirus vaccine. 

The Inovio Analyst: Cantor Fitzgerald analyst Charles Duncan reiterated an Overweight rating on Inovio shares and reduced the price target from $45 to $31. 

The Inovio Thesis: Inovio's planned Phase 3 study in at-risk volunteers with an assumed higher case rate — although encouraging — poses greater execution risk and mounting competition for clinical trial resources and in-market demand, given the progress made by other vaccine developers, Duncan said in a Tuesday note. (See his track record here.)

Cantor is taking a conservative stance and reduced its estimate for Inovio's number of doses sold in 2022-2026, the analyst said.  

Given Inovio's quarter-end cash position of $372 million, there is likely to be sufficient funding into 2023, with a bevy of potential pipeline milestones, he said. 

The 94% responder rate for the INO-4800 vaccine in the Phase 1 study and qualitative characterization of the composition of immune responses warrant movement of the investigational vaccine into a Phase 2/3 efficacy study, Duncan said. 

The analyst said he expects patient enrollment in the study to occur during the summer or early fall.

The proposed Phase 2/3 study is likely to enroll health care workers, first responders and persons in other occupations that place them at higher risk of COVID-19 infection, he said. 

The size and the speed of the study will depend on several factors, including the viral attack rate, Duncan said. 

The Rest Of Inovio's Pipeline: Inovio's other upcoming catalysts include two key data readouts from the Phase 3 REVEAL-1 and REVEAL-2 clinical studies of VGX-3100 in cervical dysplasia, the analyst said.

The company is also expected to release 18-month overall survival data from INO-5401/INO-9012/checkpoint inhibitor in glioblastoma multiforme and data from the Phase 2 study of MEDI-0457 in combination with durvalumab for metastatic HPV-related squamous cell carcinoma of the head and neck, according to Cantor Fitzgerald.

INO Price Action: Inovio shares ended Tuesday's session down 23.01% at $14.62. 

Related Links:

The Week Ahead In Biotech: Bausch Health, Fennec Pharma FDA Decisions And Smid-cap Earning

Attention Biotech Investors: Mark Your Calendar For August PDUFA Dates

Latest Ratings for INO

Jul 2020Maxim GroupDowngradesBuyHold
Jun 2020HC Wainwright & Co.DowngradesBuyNeutral
Jun 2020Cantor FitzgeraldMaintainsOverweight

View More Analyst Ratings for INO
View the Latest Analyst Ratings


Related Articles (INO)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Earnings Health Care Price Target Reiteration Analyst Ratings General Best of Benzinga

Latest Ratings

CAKEPiper SandlerMaintains38.0
AXPiper SandlerMaintains26.0
SRMorgan StanleyMaintains61.0
SOMorgan StanleyMaintains56.0
SJIMorgan StanleyMaintains21.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at